SML2076

ONO-AE3-208

≥98% (HPLC)

• Synonim(y): 4-(4-Cyano-2-(2-(4-fluoronaphthalen-1-yl)propanamido)phenyl)butanoic acid, 4-Cyano-2-[[2-(4-fluoro-1-naphthalenyl)-1-oxopropyl]amino]benzenebutanoic acid, AE3-208
• Wzór empiryczny (zapis Hilla): C₂₄H₂₁FN₂O₃
• Numer CAS: 402473-54-5
• Masa cząsteczkowa: 404.43
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD13184814
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: CC(C1=C(C=CC=C2)C2=C(F)C=C1)C(NC3=CC(C#N)=CC=C3CCCC(O)=O)=O
• InChI: 1S/C24H21FN2O3/c1-15(18-11-12-21(25)20-7-3-2-6-19(18)20)24(30)27-22-13-16(14-26)9-10-17(22)5-4-8-23(28)29/h2-3,6-7,9-13,15H,4-5,8H2,1H3,(H,27,30)(H,28,29)
• InChI key: MTDIMKNAJUQTIO-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

ONO-AE3-208 is an orally active prostaglandin E2 receptor 4 (EP4)-selective antagonist (Ki in nM = 1.3/EP4, 30/EP3, 790/FP and 2400/TP; Ki >10 μM for prostanoid receptors DP, EP1, EP2, IP). Both EP4-/- mice and ONO-AE3-208-treated wild-type mice (10 mg/kg/day in drinking water) are shown to develop severe symptoms (diarrhea, hemoccult, weight loss) in a murine model of DSS-induced colitis. ONO-AE3-208 is also reported to promote ductus arteriosus constriction among fetal and neonatal rats in vivo (10 mg/kg administered orogastrically). In addition, ONO-AE3-208 is demonstrated to effectively inhibit 1 ng/mL IL-1β-induced HUVEC migration in vitro (53% and 75% inhibition by 1 or 10 μM AE3-208, repectively) and block IL-1β (30 ng/Hydron pellet implant)-induced angionesis in mouse corneas in vivo (1 mg/kg/day p.o.).

Orally available prostaglandin E2 receptor 4 (EP4)-selective antagonist with in vitro and in vivo efficacy.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable